최소 단어 이상 선택하여야 합니다.
최대 10 단어까지만 선택 가능합니다.
다음과 같은 기능을 한번의 로그인으로 사용 할 수 있습니다.
NTIS 바로가기Respirology case reports, v.4 no.6, 2016년, pp.e00197 -
Kobayashi, Haruki (Division of Thoracic Oncology Shizuoka Cancer Center Shizuoka Japan) , Wakuda, Kazushige (Division of Thoracic Oncology Shizuoka Cancer Center Shizuoka Japan) , Takahashi, Toshiaki (Division of Thoracic Oncology Shizuoka Cancer Center Shizuoka Japan)
A 61‐year‐old never‐smoking woman with stage IV lung adenocarcinoma with initially unknown epidermal growth factor receptor (EGFR) status, lung metastasis, pleural dissemination, and malignant pleural effusion in 2007 received 10 prior anti‐cancer regimens including gefit...
1 Wu JY , Yu CJ , Chang YC , et al. 2011 Effectiveness of tyrosine kinase inhibitors on "uncommon" epidermal growth factor receptor mutations of unknown clinical significance in non‐small cell lung cancer . Clin. Cancer Res. 17 ( 11 ): 3812 – 3821 . 21531810
2 Yang JC , Sequist LV , Geater SL , et al. 2015 Clinical activity of afatinib in patients with advanced non‐small‐cell lung cancer harbouring uncommon EGFR mutations: a combined post‐hoc analysis of LUX‐Lung 2, LUX‐Lung 3, and LUX‐Lung 6 . Lancet Oncol. 16 ( 7 ): 830 – 838 . 26051236
3 Foss JF , Fisher DM , and Schmith VD 2008 Pharmacokinetics of alvimopan and its metabolite in healthy volunteers and patients in postoperative ileus trials . Clin. Pharmacol. Ther. 83 ( 5 ): 770 – 776 . 17653140
4 Yang JC‐H , Ahn M‐J , Dickgreber NJ , et al. 2015 Influence of dose adjustment on afatinib safety and efficacy in patients (pts) with advanced EGFR mutation‐positive (EGFRm+) non‐small cell lung cancer (NSCLC) . J. Clin. Oncol. 33 ( suppl ): abstract 8073.
5 Oxnard GR , Arcila ME , Chmielecki J , et al. 2011 New strategies in overcoming acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in lung cancer . Clin. Cancer Res. 17 ( 17 ): 5530 – 5537 . 21775534
※ AI-Helper는 부적절한 답변을 할 수 있습니다.